CXCL8 and COVID-19: Importantly, concomitant treatment of macrophages with SARS-CoV-2 viral proteins and exogenous RvD1 significantly reduces Macrophage Inflammatory Protein (MIP)-1α, TNF-α, and IL-8 (Recchiuti et al., 2020), further reinforcing the potential therapeutic benefit of increasing pro-resolving omega-3 PUFA-derived lipid mediators in COVID-19.